Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7726 to 7740 of 8314 results

  1. Extracorporeal membrane oxygenation (ECMO) for acute heart failure in adults (IPG482)

    This guidance has been updated and replaced by NICE interventional procedures guidance 807, 808 and 810.

  2. myCOPD for managing chronic obstructive pulmonary disease (MTG68)

    This guidance has been updated and replaced by NICE healthtech guidance 736, which covers using myCOPD for self-management of chronic obstructure pulmonary disease (COPD), and NICE healthtech guidance 718, which covers using myCOPD for pulmonary rehabilitation.

  3. Lenus COPD Support Service for remotely managing chronic obstructive pulmonary disease (MIB300)

    This advice has been updated and replaced by NICE healthtech guidance 736.

  4. Artificial intelligence for analysing chest X-ray images (MIB292)

    This medtech innovation briefing has been updated and replaced by HealthTech guidance 696

  5. Space from Depression for treating adults with depression (MIB215)

    This advice has been updated and replaced by NICE HealthTech guidance 675.

  6. Lenvatinib with pembrolizumab and transarterial chemoembolization for untreated localised hepatocellular carcinoma [ID5117]

    Discontinued Reference number: GID-TA11008

  7. Improving outcomes in urological cancers (CSG2)

    NICE has retired this cancer service guideline because the recommendations are no longer being kept up to date and may no longer reflect best practice.Retired guidance is no longer being actively maintained. The guidance has no status, and the health and care system is not expected to follow it. Retired guidance is available as a PDF for reference only.

  8. Improving supportive and palliative care for adults with cancer (CSG4)

    NICE has retired this cancer service guideline because the recommendations are no longer being kept up to date and may no longer reflect best practice.Retired guidance is no longer being actively maintained. The guidance has no status, and the health and care system is not expected to follow it. Retired guidance is available as a PDF for reference only.

  9. Improving outcomes in breast cancer (CSG1)

    NICE has retired this cancer service guideline because the recommendations are no longer being kept up to date and may no longer reflect best practice.Retired guidance is no longer being actively maintained. The guidance has no status, and the health and care system is not expected to follow it. Retired guidance is available as a PDF for reference only.

  10. Guidance on the use of long‑acting insulin analogues for the treatment of diabetes – insulin glargine (TA53)

    This guidance has been replaced by NICE guideline NG17.

  11. Farco-fill Protect for indwelling urinary catheterisation (MIB121)

    July 2021: NICE has withdrawn the medtech innovation briefing (MIB) on Farco-fill Protect for indwelling urinary catheterisation because the product has been withdrawn from the UK market.

  12. Fluorouracil chemotherapy: The My5‑FU assay for guiding dose adjustment (DG16)

    We have moved Diagnostics guidance 16 to become HealthTech guidance 360. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

  13. Detecting, managing and monitoring haemostasis: viscoelastometric point‑of‑care testing (ROTEM, TEG and Sonoclot systems) (DG13)

    We have moved Diagnostics guidance 13 to become HealthTech guidance 348. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

  14. Intraoperative tests (RD‑100i OSNA system and Metasin test) for detecting sentinel lymph node metastases in breast cancer (DG8)

    We have moved Diagnostics guidance 8 to become HealthTech guidance 315. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

  15. EGFR‑TK mutation testing in adults with locally advanced or metastatic non-small-cell lung cancer (DG9)

    We have moved Diagnostics guidance 9 to become HealthTech guidance 316. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.